

Supplementary Information for

HLA-A*03:01 is associated with increased risk of fever, chills, and more severe reaction to Pfizer-BioNTech COVID-19 vaccination

Alexandre Bolze¹, Iva Neveux², Kelly M. Schiabor Barrett¹, Simon White¹, Magnus Isaksson¹, Shaun Dabe³, William Lee¹, Joseph J. Grzymalski², Nicole L. Washington¹, Elizabeth T. Cirulli^{1*}

¹ Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401

² Center for Genomic Medicine, Desert Research Institute, 2215 Raggio Pkwy, Reno, Nevada 89512

³ Renown Health, 1155 Mill St., Reno, Nevada 89502

*Corresponding Author:

Elizabeth T. Cirulli, liz.cirulli@helix.com

Figure S1: Self-reported severity of vaccine reaction by type of vaccine, and by age.

Figure S2: Distribution of HLA-A*03:01 across the globe.

Figure S3: Rate of severe / extreme vaccine reaction by vaccine manufacturer, HLA-A*03:01 genotype, and whether participants had COVID-19 prior to the vaccine.

Figure S4: Reaction by first and second dose.

Figure S5: Fraction of individuals with severe / extreme vaccine reactions whose severe reactions subsided within two days.

Table S1: Counts of individuals by maximum reaction severity and grouped by genetic ancestry




Figure S1. Self-reported severity of vaccine reaction by type of vaccine, and by age. This analysis was limited to participants without a personal history of SARS-CoV-2 infection prior to vaccination. **A-C)** Reaction severity after dose 1 (left) and after dose 2 (right) of Pfizer-BioNTech vaccine (A); after dose 1 (left) and after dose 2 (right) of Moderna vaccine (B); after J&J vaccine (C). Columns of different colors represent the number of individuals who self-reported with a reaction of a given severity. Purple: No difficulties with daily routine. Blue: Mild difficulties with daily routine. Green: Moderate difficulties with daily routine. Orange: Severe difficulties with daily routine. Red: Extreme difficulties / unable to perform daily routine. **D)** Reactogenicity by age. For each vaccine, the mean self-reported reaction grade is plotted. 0.0: no reaction; 1.0: mild reaction; 2.0: moderate reaction; 3.0: severe reaction; 4.0 extreme reaction. In blue (rounds) for individuals 18 to 55 years old, and in orange (squares) for individuals over 55 years old. Left panel: Pfizer-BioNTech vaccine, Middle panel: Moderna vaccine. Right panel: J&J vaccine.




Figure S2. Distribution of HLA-A*03:01 across the globe. Downloaded from http://www.allelefrequencies.net/hla6008a.asp?hla_allele=A*03:01 on November 15, 2021.





Figure S3. Rate of severe / extreme vaccine reaction by vaccine manufacturer, HLA-A*03:01 genotype, and whether participants had COVID-19 prior to the vaccine. P=Pfizer-BioNTech, M=Moderna, J=Johnson&Johnson, O=Other/Unsure. Plot is restricted to European genetic ancestry individuals.

A)



B)




Figure S4. Reaction by first and second dose. A) Percent of vaccine recipients experiencing severe / extreme vaccine reaction at only the 1st dose, only the 2nd dose, or at both doses. B) MAF of HLA-A*03:01 for individuals who rated their vaccine reaction as none (0), mild (1), moderate (2), severe (3) or extreme (4) according to Table 1). At the second dose, individuals who received Pfizer had the clearest association with HLA-A*03:01. Plot is restricted to European ancestry individuals.




Figure S5. Fraction of individuals with severe / extreme vaccine reactions whose severe reactions subsided within two days. Individuals are split by which vaccine they received. Plot is restricted to European ancestry individuals.